C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/57 (2006.01) A61K 45/00 (2006.01) A61P 25/00 (2006.01) C07H 21/04 (2006.01) C07K 16/40 (2006.01) C12N 9/50 (2006.01) C12N 9/64 (2006.01) C12P 21/02 (2006.01) C12Q 1/37 (2006.01) C12Q 1/68 (2006.01) G01N 33/53 (2006.01) G01N 33/68 (2006.01)
Patent
CA 2507811
This invention refers to the recombinant human endooligopeptidase (hEOPA), polynucleotide which codes for the hEOPA, polynucleotide which allow the expression of the EOPA in prokaryotes and eukaryotes, including the human beings; use of the synthetic substrates for the determination of the proteolytic activity of the hEOPA, or of its chaperon activity or its activity as soluble peptide receptor; obtaining and using of the specific antibodies and inhibitors of its oligopeptide binding activity, as agonists, competitors and antagonists, which are able to disturb its interaction and the complex formation with other proteins. The invention also refers to the application of the natural and recombinant protein, chemically or genetically modified which aim is the diagnosis and/or the application in congenital, infectious and degenerative pathologic conditions of the central nervous system, and for psychiatric and behavioral dysfunctions. It is also proposed the application of the inhibitors and competitors for the interaction of EOPA with ligands, including antibodies or their derivatives, for the treatment of tissular and neurodegenerative pathologies.
L'invention concerne l'endooligopeptidase humaine recombinante (hEOPA), le polynucléotide qui qui code pour hEOPA, le polynucléotide qui permet l'expression d'EOPA chez les procaryotes et les eucaryotes, y compris les humains, l'utilisation de substrats synthétiques pour déterminer l'activité protéolytique de hEOPA, de son activité chaperonne ou de son activité de récepteur de peptides solubles. Elle permet d'obtenir et d'utiliser des anticorps spécifiques et des inhibiteurs de son activité de liaison d'oligopeptides en tant qu'agonistes, concurrents et antagonistes, capables de perturber son interaction et la formation de complexes avec d'autres protéines. L'invention concerne aussi l'application de la protéine naturelle ou recombinante, chimiquement ou génétiquement modifiée, dont le but est le diagnostic et/ou l'application dans des états pathologiques congénitaux, infectieux et dégénératifs du système nerveux central, et en cas de dysfonctionnements psychiatriques et comportementaux. L'invention concerne aussi l'application des inhibiteurs et des concurrents de l'invention pour l'interaction d'EOPA avec des ligands, y compris les anticorps et leurs dérivés, pour le traitement des pathologies de tissus ou neuro-dégénératives.
Camargo Antonio
Guerreiro Juliano
Hayashi Mirian
Portaro Fernanda
Camargo Antonio
Fundacao de Amparo A. Pesquisa Do Estado de Sao Paulo
Moffat & Co.
LandOfFree
Process for the determination of the primary structure of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the determination of the primary structure of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the determination of the primary structure of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1930088